You're not right in one sense Whytee but I'm sure if you were given the opportunity to purchase a good number of shares in any company @27c and could sell them at somewhere near a $1 straight away you'd consider selling some to cover the base cost. In my experience there is no such thing as a sure thing in biotech but with respect to Opthea I see a well run company with a science that appears very logical and this makes me quietly confident but, and there's always the potential for "buts" in biotech.
Ann: Appendix 3B, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.5¢ |
Change
-0.020(4.04%) |
Mkt cap ! $584.7M | |||
| Open | High | Low | Value | Volume |
| 49.5¢ | 50.8¢ | 47.5¢ | $4.304M | 9.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 29597 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 15044 | 2 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |